Overview
Optimizing the Management of Clostridium difficile Infection (CDI)
Clostridium difficile Infection: Patient Case Study
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Recorded at a prominent infectious-disease conference in October 2018, Carlene Muto, MD and Sahil Khanna, MBBS discuss new clinical practice guidelines from IDSA/SHEA and clinical best practices for optimal treatment of C. difficile infection. A C. difficile patient and survivor of 8 infection recurrences (9 total infections) also presents her story for expert panel discussion/analysis and audience questions.
This activity is intended for gastroenterologists, infectious disease specialists, pharmacists and other healthcare professionals that treat Clostridium difficile infection.
The purpose of this activity is to update physicians and pharmacists on the 2017 IDSA/SHEA guidelines for the treatment of Clostridium difficile infection and its recurrence.
Physician Learning Objectives
Upon completion of this activity, learners will be able to:
Upon completion of this activity, learners will be able to:
- Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
- Compare and contrast evidence-based approaches for the management of first and second recurrences of C. difficile infection in diverse patient populations, and appropriate targeted therapeutic selections for each.
- Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they compare with established practice patterns.
Pharmacy Learning Objectives
Upon completion of this activity, learners will be able to:
- Outline patient and clinical factors that may predict C. difficile recurrence and implement effective tools/processes to identify at-risk patients.
- Compare and contrast evidence-based approaches for medication therapy management (MTM) of first and second recurrences of C. difficile infection.
- Discuss newly released IDSA/SHEA clinical practice guidelines for C. difficile infection and how they may affect existing antimicrobial stewardship protocols
Supported by an educational grant from Merck & Company.
I. Therapeutic selection under 2018 IDSA/SHEA C. difficile Guidelines for Kathy, a patient with eight CDI recurrent infections
II. New practice guideline changes
III. Emerging treatment paradigms/research pipeline
II. New practice guideline changes
III. Emerging treatment paradigms/research pipeline
Sahil Khanna, MBBS
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Associate Professor of Medicine
Division of Gastroenterology and Hepatology
Mayo Clinic
Rochester, Minnesota
Carlene Muto, MD, MS
Associate Professor
Department of Medicine, Infectious Diseases
University of Virginia
Charlottesville, Virginia
In collaboration with: Kathy, a CDI survivor of eight recurrences.
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CPE activity.
The following financial relationships have been provided:
Sahil Khanna, MBBS
Advisory Board: Merck & Company
Consultant: Premier, Inc., Probiotech, LLC, and Shire PLC
Research Support: Rebiotix, Inc.
The following have no relevant financial relationships to disclose:
Carlene Muto, MD, MS
Kathy, a CDI survivor of eight recurrent infections
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: None
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CPE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CPE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CPE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
Inquiries may be directed to ACHL at (877) 444-8435, ext.160.
CPE credit will be submitted to CPE Monitor® on the first day of each month.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 0.5 contact hours.
ACPE Universal Activity Number: 0396-0000-18-070-H01-P
Activity Type: Knowledge